Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-31

Study Completion Date

2018-11-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

NCT04170023

Paroxysmal Nocturnal Hemoglobinuria (PNH)

TERMINATED PHASE2

Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

NCT04935294

Healthy Renal Dysfunction

COMPLETED PHASE1

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

NCT03459443

C3 Glomerulonephritis C3 Glomerulopathy Immune Complex Membranoproliferative Glomerulonephritis +2 more

TERMINATED PHASE2

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

NCT03369236

C3 Glomerulopathy C3 Glomerulonephritis Dense Deposit Disease

COMPLETED PHASE2

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

NCT03124368

C3 Glomerulonephritis Dense Deposit Disease C3 Glomerulopathy +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After 12 weeks of treatment, participants deriving clinical benefit were offered enrollment in a separate long-term extension study (ACH471-103, NCT03181633).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Danicopan

Starting doses of danicopan ranged from 100 to 150 milligrams (mg) three times daily (TID), with subsequent dose escalation up to 200 mg TID based on response (clinical and biochemical) for 28 days (Part 1). Participants with reductions in lactate dehydrogenase (LDH) meeting specified criteria were offered continued dosing beyond Day 28, for up to 8 additional weeks (Part 2).

Group Type EXPERIMENTAL

Danicopan

Intervention Type DRUG

Danicopan was administered as multiple oral doses over a period of at least 28 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Danicopan

Danicopan was administered as multiple oral doses over a period of at least 28 days.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ACH-0144471 ACH-4471 ACH4471 4471 ALXN2040

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Currently untreated PNH participants with PNH Type III erythrocyte and/or granulocyte clone size ≥10% and anemia (hemoglobin \<12 grams/deciliter) with adequate reticulocytosis (as determined by the Investigator).
* LDH ≥1.5 x the upper limit of normal.
* Platelets ≥50,000/microliter without the need for platelet transfusions.
* Documentation of vaccination for Neisseria meningitidis, Haemophilus influenza, and Streptococcus pneumoniae, or willingness to receive vaccinations during the screening period.
* Negative pregnancy test for females prior to dosing and throughout the study.

Exclusion Criteria

* History of a major organ transplant (for example, heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant.
* Participants who had received another investigational agent within 30 days or 5 half-lives of the investigational agent prior to study entry, whichever is greater.
* Participants who had received eculizumab at any dose or interval within the past 75 days before study entry.
* Participants with known or suspected complement deficiency.
* Participants with active bacterial infection or clinically significant active viral infection, a body temperature \>38°Celsius, or other evidence of infection on Day 1, or with a history of febrile illness within 14 days prior to first study drug administration.
* History of meningococcal infection, or a first-degree relative or household contact with a history of meningococcal infection.
* Females who were pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration or participants with a female partner who was pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No